Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced its participation in two major investor conferences in February 2025.

The company will engage in fireside chats at the Guggenheim SMID Cap Biotechnology Conference in New York on February 6 at 10:00 a.m. ET, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event, on February 11 at 11:20 a.m. ET.

Live webcasts of both presentations will be accessible through the Investors section under "News and Events" on Kymera's website (www.kymeratx.com). Recordings will be archived and available for viewing after the events.

01/30/2025 - 07:00 AM

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:

Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; and
Oppenheimer 35^th Annual Healthcare Life Sciences Conference held virtually on February 11 at 11:20 a.m. ET.

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor and Media Contact:

Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300

FAQ

When and where will Kymera Therapeutics (KYMR) present at the Guggenheim SMID Cap Conference?

Kymera Therapeutics will present at the Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6, 2025, at 10:00 a.m. ET.

What time is KYMR's presentation at the Oppenheimer Healthcare Conference?

Kymera Therapeutics will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 11:20 a.m. ET.

How can investors access Kymera Therapeutics' (KYMR) February 2025 conference presentations?

Investors can access live webcasts of the presentations through the "News and Events" section in the Investors area of Kymera's website at www.kymeratx.com.